JP Morgan Chase’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-305,059
| Closed | -$7.35M | – | 7538 |
|
|
2023
Q1 | $7.35M | Buy |
305,059
+265,755
| +676% | +$3.33M | ﹤0.01% | 2532 |
|
|
2022
Q4 | $416K | Buy |
39,304
+1,880
| +5% | +$15.2K | ﹤0.01% | 4636 |
|
|
2022
Q3 | $168K | Buy |
37,424
+4,574
| +14% | +$20.8K | ﹤0.01% | 5035 |
|
|
2022
Q2 | $132K | Sell |
32,850
-2,009
| -6% | -$9.52K | ﹤0.01% | 5284 |
|
|
2022
Q1 | $255K | Buy |
34,859
+6,280
| +22% | +$37.6K | ﹤0.01% | 5062 |
|
|
2021
Q4 | $160K | Buy |
28,579
+2,109
| +8% | +$13.4K | ﹤0.01% | 5471 |
|
|
2021
Q3 | $169K | Buy |
26,470
+1,084
| +4% | +$6.97K | ﹤0.01% | 5324 |
|
|
2021
Q2 | $213K | Buy |
25,386
+4,493
| +22% | +$36.3K | ﹤0.01% | 5214 |
|
|
2021
Q1 | $220K | Sell |
20,893
-1,206
| -5% | -$17K | ﹤0.01% | 5112 |
|
|
2020
Q4 | $374K | Buy |
22,099
+4,355
| +25% | +$65.3K | ﹤0.01% | 4537 |
|
|
2020
Q3 | $226K | Buy |
17,744
+3,486
| +24% | +$44K | ﹤0.01% | 4305 |
|
|
2020
Q2 | $201K | Buy |
+14,258
| New | +$180K | ﹤0.01% | 4251 |
|
|
2019
Q1 | – | Sell |
-60
| Closed | – | – | 6125 |
|
|
2018
Q4 | $0 | Buy |
+60
| New | +$172 | ﹤0.01% | 6019 |
|
Other funds holding PRVB
JP Morgan Chase's PRVB Position: Q2 2023 in Review
JP Morgan Chase sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 305,059 shares — an estimated $7.35M sold.
JP Morgan Chase first reported a position in PRVB in Q4 2018 and held it in 13 quarters. The position peaked at $7.35M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- JP Morgan Chase reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- JP Morgan Chase sold 305,059 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $7.35M.
- JP Morgan Chase first reported a position in Provention Bio, Inc. Common Stock in Q4 2018 and held it in 13 quarters.
- JP Morgan Chase's Provention Bio, Inc. Common Stock position peaked at $7.35M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.